UF startup and UF Innovate | Sid Martin Biotech resident client TearClear, an emerging ophthalmic pharmaceutical company, announced successful completion of pre-IND (Investigational New Drug) meeting with the U.S. Food and Drug Administration (FDA) regarding the development plan for the preservative free multi-dose delivery of a proprietary Latanoprost formulation, including the clinical study design for the registration study.